to bispecific antibodies and chimeric antigen receptors for cell-based therapies. RubrYc’s collaboration model includes options for co-discovery and co-development programs, for out-licensing or ...

Chimeric mAbs were less evident ... this class of mAbs has been the main source of antibody-based products entering clinical studies since 1997. Figure 1: Number of mAbs entering clinical studies ...

The research paper titled "Recruiting the Immune System against Pathogenic Bacteria Using High-Affinity Chimeric Tags" is published in the journal Bioconjugate Chemistry. Pathogens often escape ...

One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...